Jefferies Goes All-In on Biotech: 5 Buy-Rated Stocks Poised for Big 2026 Catalysts

Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228).